IMS Health and Foundation Medicine Announce Collaboration to Optimize Targeting of Precision Therapies in Oncology

Extends and Integrates IMS Health Real-World Evidence Platform with FoundationCORE for Outcomes Insights, Commercialization Strategies

June 22, 2015 09:00 AM Eastern Daylight Time
DANBURY, Conn. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMS Health (NYSE:IMS) and Foundation Medicine, Inc. (NASDAQ:FMI) today announced a collaboration to advance the understanding and effectiveness of precision medicines for treating cancer. Commercial, medical and outcomes research teams in biopharma and life sciences companies will now be able to leverage an offering that combines IMS Health's powerful Real-World Evidence (RWE) platform providing clinical and cost-of-care insights with Foundation Medicine's dynamic knowledgebase of comprehensive cancer genomic profiles, all at the patient-anonymous level.

"There is recognition within the healthcare industry that rich and highly credible information will be the primary catalyst for the broad adoption of precision medicine, particularly in oncology"

Through the collaboration, IMS Health's clients will gain unprecedented insights to rapidly assess health outcomes and effectiveness, and to improve cancer care by better connecting patients to the right targeted therapies at the right time.

"As life sciences companies look to deploy new, targeted therapies that address the unique molecular drivers of specific cancers, it has become increasingly important for them to better understand unmet needs, treatment decisions and outcomes for patient populations living with those cancers," said Jon Resnick, IMS Health vice president and general manager of Real-World Evidence Solutions. "This collaboration with Foundation Medicine extends our Real-World Evidence platform – uniquely linking claims, EMR and biomarker data at the anonymous patient level to drive a complete understanding of the oncology patient journey and improve clinical development and commercialization strategies."

These enhanced oncologic insights will be powered by Evidence 360™ and FoundationCORE™. Evidence 360 is IMS Health's scalable and secure RWE platform that helps clients extract, analyze and visualize real-world data to better understand and measure healthcare outcomes. It brings together IMS Health's vast library of patient-anonymous data with other patient-anonymous sources of health information to help life sciences companies interpret real-world outcomes and better target their commercial efforts. FoundationCORE is a molecular information knowledgebase containing comprehensive cancer genomic information and insights from more than 43,000 clinical cases profiled by Foundation Medicine. FoundationCORE evolves in real-time, informed by every new cancer patient tested with the company's commercial assays, FoundationOne® and FoundationOne® Heme.

"There is recognition within the healthcare industry that rich and highly credible information will be the primary catalyst for the broad adoption of precision medicine, particularly in oncology," said Michael J. Pellini, M.D., chief executive officer of Foundation Medicine. "As the leader in molecular information solutions, Foundation Medicine's collaboration with IMS Health expands existing relationships with our biopharma partners, further underscoring the value of FoundationCORE and its impact on informing physicians and patients, and transforming clinical practice."

About IMS Health

IMS Health (NYSE:IMS) is a leading global information and technology services company providing clients in the healthcare industry with comprehensive solutions to measure and improve their performance. End-to-end proprietary applications and configurable solutions connect 10+ petabytes of complex healthcare data through the IMS One™ cloud platform, providing comprehensive insights into diseases, treatments, costs and outcomes. The company's 15,000 employees blend global consistency and local market knowledge across 100 countries to help clients run their operations more efficiently. Customers include pharmaceutical, consumer health and medical device manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community.

As a global leader in protecting individual patient privacy, IMS Health uses anonymous healthcare data to deliver critical, real-world disease and treatment insights. These insights help biotech and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders to identify unmet treatment needs and understand the effectiveness and value of pharmaceutical products in improving overall health outcomes. Additional information is available at

About Foundation Medicine

Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's clinical assays, FoundationOne® for solid tumors and FoundationOne® Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine®, FoundationOne® and FoundationCORE™ are trademarks of Foundation Medicine, Inc.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding any information offerings to be provided through the collaboration and the ability of any information offerings to advance precision medicine for cancer, including increasing adoption. All such forward-looking statements are based on the current expectations by the management teams of IMS Health and Foundation Medicine of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that the information offerings are not widely accepted, and the other risks described under the caption "Risk Factors" in the respective Annual Reports on Form 10-K for each of IMS Health and Foundation Medicine for the year ended December 31, 2014, which are on file with the Securities and Exchange Commission, as well as other risks detailed in subsequent filings with the Securities and Exchange Commission for each of IMS Health and Foundation Medicine. All information in this press release is as of the date of the release, and neither IMS Health nor Foundation Medicine undertakes a duty to update this information unless required by law.

IMS Health
Tor Constantino, +1-484-567-6732
Media Relations
[email protected]
Foundation Medicine
Susan Hager, +1-617-418-2258
[email protected]